NEVVI Medicare utilization intelligence
or

← back

Provider profile

JAGTAP, DEEPA M.D.

Hematology-Oncology · NPI 1629190095 · ROYAL OAK, MI

1
Groups
50
Codes · 2024
61,537
Disclosed services

JAGTAP, DEEPA is a Hematology-Oncology in ROYAL OAK, MI, a member of 1 medical group, who billed 50 distinct codes to Medicare Part B in 2024.

Groups: MICHIGAN HEALTHCARE PROFESSIONALS PC (FARMINGTON HILLS, MI)

Year: 2024 · 2023 · 2022 🔒 · 2021 🔒 · 2020 🔒

Provider overview · all codes · CY2024

61,537
disclosed services
50
codes billed to Medicare Part B
Prior year · CY2023 111,459 disclosed services

This provider's disclosed Medicare payments across all codes were in CY2024.

Dollars, place-of-service mix, business mix and national standing are part of the market analytics platform — built, not launched yet. Notify me at launch →

All figures are disclosed (CMS suppresses fewer-than-11-beneficiary rows) Medicare Part B fee-for-service — a subset, never complete totals; volumes are personal to this NPI, not attributed to any group. Standing is a billed-volume position among specialty peers with disclosed billing (national percentile; a provider's true standing can only be higher, never lower), not a statement about care. See Methods & Sources.

Procedures billed to Medicare Part B (2024)

Medicare Part B FFS · CY2024 · as published by CMS
This provider's Medicare volumes — services, beneficiary-episodes, and charges — are part of the market analytics platform — built, not launched yet. Notify me at launch →
CodeDescription Services Beneficiary-episodes Avg charge Avg Medicare payment
J1439 Injection, ferric carboxymaltose, 1 mg
Q0138 Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use)
J0897 Injection, denosumab, 1 mg
J9271 Injection, pembrolizumab, 1 mg
J1453 Injection, fosaprepitant, 1 mg
J0881 Injection, darbepoetin alfa, 1 microgram (non-esrd use)
J1449 Injection, eflapegrastim-xnst, 0.1 mg
J0885 Injection, epoetin alfa, (for non-esrd use), 1000 units
J1566 Injection, immune globulin, intravenous, lyophilized (e.g., powder), not otherwise specified, 500 mg
36415 Insertion of needle into vein for collection of blood sample
85025 Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count
J2469 Injection, palonosetron hcl, 25 mcg
J1100 Injection, dexamethasone sodium phosphate, 1 mg
80048 Blood test, basic group of blood chemicals (calcium, total)
G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's
80076 Liver function blood test panel
99214 Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more
84100 Phosphate level
83615 Lactate dehydrogenase (enzyme) level
84550 Uric acid level, blood
96372 Injection of drug or substance under skin or into muscle
99213 Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more
J0640 Injection, leucovorin calcium, per 50 mg
96375 Injection of additional new drug or substance into vein
83735 Magnesium level
99215 Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more
99232 Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes
96413 Administration of chemotherapy into vein, 1 hour or less
J9190 Injection, fluorouracil, 500 mg
J3489 Injection, zoledronic acid, 1 mg
96366 Infusion into a vein for therapy, prevention, or diagnosis, each additional hour
99231 Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes
96401 Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle
J3420 Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg
J3475 Injection, magnesium sulfate, per 500 mg
96360 Infusion into a vein for hydration, 31-60 minutes
96365 Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less
99223 Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes
J1200 Injection, diphenhydramine hcl, up to 50 mg
96367 Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less
96417 Administration of additional new drug or substance into vein, 1 hour or less
96415 Administration of chemotherapy into vein, each additional hour
96374 Injection of drug or substance into vein
96361 Infusion into a vein for hydration, each additional hour
99205 New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more
80053 Blood test, comprehensive group of blood chemicals
99233 Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes
99195 Drawing of blood for a medical problem
90662 Influenza vaccine split virus, preservative free
G0008 Administration of influenza virus vaccine

These are this provider's own Medicare Part B fee-for-service volumes (CMS public data). CMS suppresses rows with fewer than 11 beneficiaries, so low-volume codes may be missing entirely — absence is not zero. Beneficiary-episodes count CMS's per-setting beneficiary figures, not unique patients. Average charge and average Medicare payment are weighted by service volume across office and facility settings. Volumes on this page are personal to the NPI and are not attributed to any physician group. See Methods & Sources.